Law Firm of Wohl & Fruchter LLP Announces Investigation of Vanda Pharmaceuticals, Inc.

  Law Firm of Wohl & Fruchter LLP Announces Investigation of Vanda
  Pharmaceuticals, Inc.

Business Wire

NEW YORK -- June 19, 2013

The law firm of Wohl & Fruchter LLP announces that it is investigating
possible violations of federal securities laws by officers and directors of
Vanda Pharmaceuticals, Inc. (Vanda) (NASDAQ: VNDA).

Vanda is a biopharmaceutical company that engages in the development and
commercialization of products for the treatment of central nervous system
disorders. One of its drugs in clinical development, Tasimelteon, has
completed two Phase III clinical trials for the treatment of circadian rhythm
sleep disorders.

On May 31, 2013, Vanda announced the submission of a New Drug Application
(NDA) to the U.S. Food and Drug Administration (FDA) for Tasimelteon. The NDA
seeks FDA approval of Tasimelteon for the treatment of Non-24-Hour Disorder
(Non-24), a sleep disorder that affects the totally blind, based on the
results of Vanda’s Phase III trials of the drug.

On June 19, 2013, an article appeared on theStreet.com claiming that a
detailed analysis of Vanda’s Phase III trials reveals a large number of
irregularities and red flags. Among other issues, the article cites multiple
changes in the primary endpoint over the course of the trials, including a
change just one month before study results were announced to a new primary
endpoint that has allegedly never been used before in sleep-drug clinical
trials, and that was not endorsed by the FDA. The article also states that
Vanda was forced to cut patient enrollment in the clinical trials in half
because an insufficient number of totally blind patients with Non-24 could not
be identified, and that ultimately less than 5% of the patients enrolled in
the trials suffered from Non-24 according to the "textbook definition" of the
disease.

Following publication of the Street.com article, VNDA dropped over 24% from a
close of $10.92/share on June 18, 2013, to $8.28/share shortly after noon
during trading on June 18, 2013.

Additional information is available on our website at:
http://www.wohlfruchter.com/cases/vnda.

Persons with relevant information, and VNDA shareholders with questions about
this investigation, are invited to contact the attorney below, or our Firm by
calling 866.582.8140.

About Wohl & Fruchter

Wohl & Fruchter LLP represents plaintiffs in litigation arising from fraud and
other fiduciary breaches by corporate managers, as well as other complex
litigation matters. Please visit our website, www.wohlfruchter.com, to learn
more about our Firm, or contact one of our partners.

Contact:

J. Elazar Fruchter (jfruchter@wohlfruchter.com)
845.425.4658 or Toll Free 866.582.8140
Wohl & Fruchter LLP
570 Lexington Avenue
New York, NY 10022
www.wohlfruchter.com

This release may be deemed to constitute attorney advertising.

Contact:

Wohl & Fruchter LLP
J. Elazar Fruchter
845.425.4658 or Toll Free 866.582.8140
jfruchter@wohlfruchter.com